Latest News

KALBE ANNOUNCE 3 RECIPIENTS OF RESEARCH FUNDING OF THE RISTEK/BRIN KALBE SCIENCE AWARD (RKSA) 2021

KALBE ANNOUNCE 3 RECIPIENTS OF RESEARCH FUNDING OF THE RISTEK/BRIN KALBE SCIENCE AWARD (RKSA) 2021

Press Release No. 049/KFCP-DIR/PR/IX/21

Jakarta, 18 September 2021, PT Kalbe Farma Tbk (Kalbe) today announced the 3 recipients of the grant for best researches of the Research and Technology/BRIN Kalbe Science Award (RKSA) 2021 which have been rigorously selected from 9 grant recipients candidates out of 282 research titles that were received by The 2021 RKSA Jury from all over Indonesia.  The three recipients of the RKSA grant will further develop their research in order to realize the RKSA 2021 mission, i.e. Downstreaming Research to Make the Nation Healthy. RKSA 2021 is a program to provide research grants for researchers in Indonesia with the theme Farma and Biopharma, Cell and gene therapy, e-health, medical devices, diagnostics, health food and drinks, and natural product products. The results of the research are hoped to be able to achieve the downstream process to become a product or service that can be enjoyed by the community. The announcement of the 3 recipients of RKSA research grants was carried out in conjunction with a scientific discussion with the theme "Digital Optimization to Support Research Downstream" with Prof. Widodo, S.Si., M.Sc., Ph.D.Med.Sc – Dean of the Faculty of Mathematics and Natural Sciences, Universitas Brawijaya and Dr. dr. Bayu Prawira Hie, MBA – Chairman of the Supervisory Board of the Indonesian Telemedicine Alliance (ATENSI).

 

The selection of proposals made by the Jury refers to the assessment criteria that have been determined, namely product and market readiness in terms of advantages over identical or similar products and benefits for users; a combination of Technology Readiness Level (TRL) and Demand Readiness Level (DRL); compatibility of the research methodology with the research objectives; the compatibility of the budget (RAB) with the research objectives and the compatibility between the timeline and the research objectives. 

 

The three recipients of the 2021 RKSA funds are:

1.        David S. Perdanakusuma with the research title The Effectiveness of the Umbilical Cord Mesenchymal Stem Cell-Secretome (UCMSC-S) Gel Against Acceleration of Wound Re-epithelialization.

2.       Bintang Soetjahjo with the research title of Effectiveness of Provision of Therapy Media Conditioned with Allogeneic Mesenchymal Umbilical Cord Stem Cells in Osteoarthritis Patients of the Knee Joint.

3.       Alex Lukmanto Suherman with the research title Development of a Rapid Test Kit Based on Single-Entity Electrochemistry (SEE) for the Detection of Covid-19 in Saliva.

 

“We appreciate Kalbe for conducting RKSA since 2008 and hope that through this RKSA program it can support research products that are ready to be downstreamed. Therefore, RKSA can encourage researchers to be more diligent in translating their research results into products or goods or services that can be used by the community to make the nation healthy," said Dr. Laksana Tri Handoko, M.Sc., Head of the National Research and Innovation Agency (BRIN). "BRIN as a facilitator of researchers in Indonesia is committed to continuing to support the RKSA program so that it becomes a role model for researchers to innovate and research for products that can be used by the community to make the nation healthy," added Dr. Handoko.

 

"RKSA 2021 is the result of collaboration between the Ministry of Research and Technology / BRIN and Kalbe in strengthening the triple helix collaboration between Academics, Business and Government, and other research communities to increase the downstreaming of research in the health sector," said Vidjongtius, President Director of PT Kalbe Farma Tbk. "Since 2018, RKSA has focused on providing research grants for selected researchers to be supported towards the downstream process of the research in order for the research results to be enjoyed by the general public," Vidjongtius continued.

 

Vidjongtius added that there were 282 research titles received this year, which were then selected into 30 proposals to become 9 finalists who presented their research in front of the jury. The research categories are Pharmacy and Biopharma, Cell and genetherapy, e-health, medical devices, diagnostics, health food and drink and natural products. "Kalbe continues to be committed to the world of research, especially in the health sector and hopes that this downstream process can produce products that can be used by the community to make the nation healthy," continued Vidjongtius.

 

The process of organizing the 2021 RKSA went through several stages, namely the pre-proposal acceptance stage in January - April, the pre-proposal assessment in May - June. The next stage was the acceptance of proposals in July, assessment of proposals in August and announcement of research proposals that will receive research funding in September 2021. For one year the researches will go through a monitoring and evaluation process by the 2021 RKSA board of juries, and 3 recipients of the research funds will be announced.

 

In the webinar RKSA, also delivered the optimization of digital to support the downstreaming of research, especially through the COVID-19 pandemic, which was delivered by Prof. Widodo, S.Si., M.Sc., Ph.D.Med.Sc – Dean of the Faculty of Mathematics and Natural Sciences, Universitas Brawijaya; and Dr. dr. Bayu Prawira Hie, MBA – Chairman of the Supervisory Board of the Indonesian Telemedicine Alliance (ATENSI).

 

conveying that seeing genetic variation can be done by preparing a functional appropriate to the genetic character.

 

Prof. Widodo, S.Si., M.Si., Ph.D.Med.Sc conveyed that "digital technology plays an important role in research in the health sector, for example, is the making vaccines which initially had to go through numerous research processes, from checking the type of virus, multiplying the virus, screening, efficacy, clinical trial stages, and general utilization. Meanwhile, with digital technology, we can accelerate research time using Bioinformatics AI and BIGData."

Dr. dr. Bayu Prawira Hie, MBA also added that in the current COVID-19 pandemic situation, communication and information platforms, especially those related to health services, are required to be digital-based so that telemedicine services which include consulting services with doctors, delivering drugs, making doctor's appointments; are carried out to reduce the risk of COVID-19 transmission and realizing adequate health services for all Indonesian people.

 

The Board of Juries of the RKSA 2021 consists of Prof. Dr. Amin Soebandrio, Ph.D, Sp.MK. (Director of the Eijkman Molecular Biology Agency), Dr. Ir. Bambang Setiadi, IPU (Chairman of the National Research Board), Dr. Ir.  Roy Alexander Sparringa, M.App.SC. (Senior Advisor of BPPT), Dr. Lucia Rizka Andalusia, Apt,. M. Pharm, MARS, (Director of Registration of the Food and Drugs Monitoring Agency), dr. Sandy Qlintang (Director of the Stem Cell and Cancer Institute & Pharma Metric Labs of PT Kalbe Farma Tbk), as well as honorable judges from the Ministry of Ristek/BRIN, and the founder of PT Kalbe Farma Tbk, Dr.  Boenjamin Setiawan, Ph.D.

 

Information on the 2021 RKSA program can be seen at www.kalbe-rksa.com.

 

 

Kalbe at a glance

 

PT Kalbe Farma Tbk ("Kalbe") was established in 1966 and is one of the largest listed pharmaceutical companies in Southeast Asia. Kalbe has four main divisions that handle reliable and varied brand portfolio: prescription medicines (Cefspan, Brainact, Broadced, etc.); health product division that handles over-the-counter medication (Promag, Mixagrip, Komix, Woods, Fatigon, etc.); multivitamins (Fatigon, H2, XonCe, Hevit-C, JossC1000, etc.);  as well as supplement and ready-to-consume drinks (Hydro Coco, Extra Joss); nutrition division (ChilKid, Prenagen, Diabetasol, Zee, etc,); and distribution division. Kalbe now has more than 40 subsidiaries, 14 production facilities with international standards, and employs approximately 17,000 employees, spread in more than 76 branches throughout Indonesia. Since 1991, Kalbe is listed on the Indonesia Stock Exchange (IDX: KLBF).


Print
461 Rate this article:
No rating

Please login or register to post comments.

Name:
Email:
Subject:
Message:
x